ATE497165T1 - Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung - Google Patents

Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung

Info

Publication number
ATE497165T1
ATE497165T1 AT05807568T AT05807568T ATE497165T1 AT E497165 T1 ATE497165 T1 AT E497165T1 AT 05807568 T AT05807568 T AT 05807568T AT 05807568 T AT05807568 T AT 05807568T AT E497165 T1 ATE497165 T1 AT E497165T1
Authority
AT
Austria
Prior art keywords
cancer cells
neu
treatment
circulative
detection
Prior art date
Application number
AT05807568T
Other languages
English (en)
Inventor
Robert Lorence
Ming Lu
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE497165T1 publication Critical patent/ATE497165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05807568T 2004-10-06 2005-10-06 Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung ATE497165T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61633204P 2004-10-06 2004-10-06
PCT/US2005/035894 WO2006041959A2 (en) 2004-10-06 2005-10-06 Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
ATE497165T1 true ATE497165T1 (de) 2011-02-15

Family

ID=36148887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05807568T ATE497165T1 (de) 2004-10-06 2005-10-06 Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung

Country Status (9)

Country Link
US (2) US20080261243A1 (de)
EP (1) EP1797431B1 (de)
JP (1) JP4798801B2 (de)
CN (1) CN101036055B (de)
AT (1) ATE497165T1 (de)
CA (1) CA2582713A1 (de)
DE (1) DE602005026143D1 (de)
MX (1) MX2007004079A (de)
WO (1) WO2006041959A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034628B4 (de) * 2005-07-19 2007-08-23 Epigenomics Ag Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA
EP1803822A1 (de) * 2005-12-30 2007-07-04 Adnagen AG Verfahren zur individuellen Charakterisierung therapeutischer Zielmoleküle und seine Anwendung
CA2647843A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
DE602007008080D1 (de) 2006-04-18 2010-09-09 Wellstat Biologics Corp Detektion von zirkulierenden endothelzellen
JP5078100B2 (ja) * 2006-04-18 2012-11-21 ウェルスタット バイオロジクス コーポレイション 循環癌細胞におけるステロイド受容体の検出および処置
US20080200342A1 (en) * 2007-02-15 2008-08-21 Rao Rupa S Device, Array, And Methods For Disease Detection And Analysis
EP2145188A4 (de) * 2007-04-19 2010-06-30 Wellstat Biologics Corp Nachweis von her2/neu-protein aus nichtisolierten zirkulierenden krebszellen und behandlung
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
JP5040597B2 (ja) * 2007-11-06 2012-10-03 日本電気株式会社 評価システム、評価方法および評価プログラム
EP2133433A1 (de) * 2008-06-09 2009-12-16 Centre Georges François Leclerc Verfahren zur Vorhersage der Reaktion auf eine Behandlung mit einem Antikörper gegen HER2
CA2779436A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN101880650B (zh) * 2009-05-04 2013-01-16 卢焕梅 一种从外周血中快速提取循环的非血缘性有核细胞的组合物和试剂盒及其应用
EP3306321A1 (de) * 2010-07-07 2018-04-11 The Regents of The University of Michigan Diagnose und behandlung von brustkrebs
FR2976294B1 (fr) 2011-06-10 2018-02-16 Universite De Nice Sophia Antipolis Methode de prediction de la reponse a un traitement avec un agent bloquant her2
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
CN104561246B (zh) * 2013-10-18 2018-06-15 深圳先进技术研究院 血液中循环癌细胞的检测信号放大的方法与试剂盒
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
CN104458710B (zh) * 2014-12-09 2017-11-14 山东省海盟生化科技有限公司 肿瘤早期高通量电化学发光检测方法的构建
CN106932583A (zh) * 2015-12-29 2017-07-07 北京大成生物工程有限公司 人表皮生长因子受体Her-2/neu定量检测试剂盒及其制备方法与应用
CN106226374B (zh) * 2016-08-18 2018-10-16 中南大学 一种人类表皮生长因子受体-2浓度的检测方法
CN106319069B (zh) * 2016-09-28 2020-02-14 河南乾坤科技有限公司 一种精确测定病源细胞的试剂盒及其应用
JP2021519284A (ja) * 2018-03-27 2021-08-10 ラボラトリー コーポレイション オブ アメリカ ホールディングス 治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ
WO2020142313A1 (en) * 2019-01-03 2020-07-09 Meso Scale Technologies, Llc Compositions and methods for carrying out assay measurements
CN111257310B (zh) * 2020-03-10 2023-05-02 莆田学院附属医院（莆田市第二医院） 一种用于癌细胞识别的电致化学发光传感器的制备方法
CN117074692B (zh) * 2023-08-15 2024-04-09 复旦大学附属华山医院 一种关于脑脊液中肿瘤细胞her2抗原表达生物信息的识别方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
EP0871887B1 (de) * 1995-06-07 2007-03-28 BioVeris Corporation Elektrochemilumineszenz-enzymimmunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
EP1231944A2 (de) * 1999-11-15 2002-08-21 University Of Southern California Zielgerichte abgabe von therapeutika und diagnostika
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
EP1360496A4 (de) * 2001-02-16 2005-03-09 Immunivest Corp Verfahren und reagenzien zur schnellen und effizienten isolierung zirkulierender krebszellen
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
ATE479490T1 (de) * 2001-10-11 2010-09-15 Aviva Biosciences Corp Verfahren zum trennen von seltenen zellen von fluidproben
EP2263691B1 (de) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Behandlung von Krebs mit dem rekombinanten, humanisierten, monoklonalen Anti-ERBB2-Antikörper 2C4 (rhuMAb 2C4)
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (de) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen
DE602007008080D1 (de) * 2006-04-18 2010-09-09 Wellstat Biologics Corp Detektion von zirkulierenden endothelzellen
JP5078100B2 (ja) * 2006-04-18 2012-11-21 ウェルスタット バイオロジクス コーポレイション 循環癌細胞におけるステロイド受容体の検出および処置
CA2647843A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells

Also Published As

Publication number Publication date
CN101036055B (zh) 2011-06-29
DE602005026143D1 (de) 2011-03-10
EP1797431A2 (de) 2007-06-20
CN101036055A (zh) 2007-09-12
EP1797431A4 (de) 2008-07-09
CA2582713A1 (en) 2006-04-20
MX2007004079A (es) 2007-06-15
US20080261243A1 (en) 2008-10-23
US20110070598A1 (en) 2011-03-24
HK1103439A1 (en) 2007-12-21
WO2006041959A2 (en) 2006-04-20
WO2006041959A8 (en) 2008-01-31
WO2006041959A3 (en) 2006-06-15
JP2008517253A (ja) 2008-05-22
JP4798801B2 (ja) 2011-10-19
EP1797431B1 (de) 2011-01-26

Similar Documents

Publication Publication Date Title
ATE497165T1 (de) Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung
Giatromanolaki et al. Autophagy and lysosomal related protein expression patterns in human glioblastoma
WO2017139587A3 (en) Anti-dengue virus ns1 protein monoclonal antibodies
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
BRPI0408315A (pt) anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
Cheng et al. Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer
Akahoshi et al. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
DE602005021644D1 (de) Verfahren und reagentien zur diagnose von hantavirusinfektionen
Castillo et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia.
RU2012148816A (ru) Метод диагностики для определения клеток ex vivo
ATE430935T1 (de) Nachweis und behandlung von prostatakrebs
Qiu et al. Identification of a TNF-α inducer MIC3 originating from the microneme of non-cystogenic, virulent Toxoplasma gondii
Mortensen et al. Quality of life in patients with multiple myeloma: a qualitative study
Kashyap et al. High-voltage pulsed electric fields and pH shift process for protein and solute release from Gracilaria sp., red edible seaweed
Hosry et al. Clinicopathologic characteristics and outcomes of transformed diffuse large B‐cell lymphoma in hepatitis C virus‐infected patients
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
CN107255711B (zh) 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途
Wang et al. Quantitative proteomic analysis of the effects of melatonin treatment for mice suffered from small intestinal damage induced by γ-ray radiation
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
WO2019066620A3 (ko) 항 c-met 항체 및 이의 용도
WO2004041076A3 (en) Methods of detecting colorectal cancer
Kurata et al. Nestin expression as an independent indicator of poor prognosis for patients with anaplastic thyroid cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties